Rapport Therapeutics, Inc.
RAPP
$10.01
-$0.46-4.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 118.38% | 170.42% | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.56% | 129.57% | -- | -- | -- |
| Operating Income | -93.56% | -129.57% | -- | -- | -- |
| Income Before Tax | -55.37% | -125.18% | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -55.34% | -125.11% | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -55.34% | -125.11% | -- | -- | -- |
| EBIT | -93.56% | -129.57% | -- | -- | -- |
| EBITDA | -92.62% | -127.95% | -- | -- | -- |
| EPS Basic | 88.18% | 38.90% | -- | -- | -- |
| Normalized Basic EPS | 86.48% | 53.14% | -- | -- | -- |
| EPS Diluted | 88.18% | 38.90% | -- | -- | -- |
| Normalized Diluted EPS | 86.48% | 53.14% | -- | -- | -- |
| Average Basic Shares Outstanding | 1,627.86% | 1,272.44% | -- | -- | -- |
| Average Diluted Shares Outstanding | 1,627.86% | 1,272.44% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |